DAFNA Funds Buy $2 Million Of Stereotaxis Debt With Rights To Convert Into Shares
The notes pay 10% annual interest, while an ownership cap blocks conversion of the funds' preferred stock.
DAFNA funds bought $2 million of Stereotaxis convertible notes Monday, adding rights to future common shares to their existing investment. The funds' SEC ownership amendment, filed Thursday, counted those conversion rights toward a 15.1% position overseen by DAFNA Capital Management.
10% Interest, Plus Conversion Rights
The notes pay 10% annual interest and let holders exchange principal and accrued interest for common stock. Their initial conversion price is $1.21 per share, with a 19.9% beneficial-ownership cap limiting conversion.
DAFNA LifeScience and DAFNA LifeScience Select, the investment funds that bought the notes, used their working capital for the purchase. Holders can elect to convert before maturity and certain corporate events.
The principal alone carries rights to 1,652,892 common shares. Conversion would issue shares to the funds, expanding the common-share count; the ownership calculation already includes those rights.
Common Shares Count, Preferred Shares Wait
The funds held 13,680,554 common shares alongside the note-conversion rights. They also owned 8,000 preferred shares, which were excluded from reported beneficial ownership because a separate 4.99% cap prevented conversion at the filing date.
LifeScience reported 8,005,938 shares, or 7.9% of the class, including its conversion rights. Select reported 7,327,508 shares, or 7.3%, on the same basis.
The percentages used 100,202,178 common shares outstanding as of July 31, 2026, plus the shares obtainable through conversion of the funds' note principal. That basis combines existing stock with potential shares from the notes.
A Board Member's Separate Shares
Dr. Nathan Fischel, DAFNA's chief executive and a Stereotaxis board member, reported 15,628,395 shares, or 15.3%. His total includes the funds' position and 294,949 restricted common shares awarded for board service that had vested or would vest within 60 days of the filing.
DAFNA is both investment manager and general partner of the funds, with voting and investment power over their securities. DAFNA and its chief investment officer, Dr. Fariba Ghodsian, each reported beneficial ownership of 15,333,446 shares, or 15.1%; these overlapping disclosures describe the same fund securities.
The investment relationship predates the note purchase. The reporting group's initial ownership disclosure was filed October 11, 2016, followed by amendments on January 9, February 6 and February 14, 2017, and March 8, 2018.
The funds now hold interest-paying debt with common-stock conversion rights alongside their common and preferred shares, with different ownership caps governing the two convertible instruments.